410 related articles for article (PubMed ID: 29969297)
1. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
2. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?
Önder S; Ozturk M
Cutan Ocul Toxicol; 2020 Mar; 39(1):31-35. PubMed ID: 31642341
[No Abstract] [Full Text] [Related]
3. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
[No Abstract] [Full Text] [Related]
5. Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria.
Ertaş R; Özyurt K; Karakükçü Ç; Akkuş MR; Özlü E; Avcı A; Atasoy M
Turk J Med Sci; 2018 Dec; 48(6):1255-1262. PubMed ID: 30541255
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count.
Tamer F
Cutan Ocul Toxicol; 2020 Sep; 39(3):229-232. PubMed ID: 32380865
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
9. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
11. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria.
de Montjoye L; Darrigade AS; Giménez-Arnau A; Herman A; Dumoutier L; Baeck M
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):55-66. PubMed ID: 31965967
[No Abstract] [Full Text] [Related]
12. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
Syrigos N; Grapsa D; Zande M; Tziotou M; Syrigou E
Int J Dermatol; 2018 Apr; 57(4):417-422. PubMed ID: 29399789
[TBL] [Abstract][Full Text] [Related]
13. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
14. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
15. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
18. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
19. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
Eghrari-Sabet J; Sher E; Kavati A; Pilon D; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Bernstein JA
Allergy Asthma Proc; 2018 May; 39(3):191-200. PubMed ID: 29458456
[TBL] [Abstract][Full Text] [Related]
20. Use of omalizumab in the treatment of chronic urticaria.
Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
